Trend
DailyUptrend (starting)
4 hourExpanding
1 hourStrong Bullish
15 minStrong Bullish
5 minStrong Bearish
Daily trend turns down below $3.78
Key levels
Resistance$5.78
Resistance$5.25
Support$4.68
Support$4.25
Latest news & SEC filings
AnalystStifel lifts its rating on Treace Medical Concepts
AnalystStifel raises Treace Medical Concepts to Buy, price target to $6.5
EarningsTreace Medical Concepts posts third quarter 2026 financial results
ProductTreace Medical launches Tailorplasty MIS system for tailor's bunion correction
All TMCI news →Treace Medical Concepts is a medical technology company that develops surgical systems for correcting bunions and related midfoot deformities. Its offerings include the Lapiplasty 3D Bunion Correction System, the Adductoplasty midfoot correction system, minimally invasive osteotomy systems, and implants for fusing the great toe joint. The company markets its products across the United States through its own sales team and independent agencies, serving foot and ankle specialists.
Based on the company's 10-K filed Feb 27, 2026.
Nasdaq · Healthcare
SEPT Low Target
$5.00
SEPT Mid Target
$5.00
SEPT High Target
$5.00
Analyst Consensus
$5.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for TMCI.
Start Free Trial →Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$4.38
35
Moat Score
NONE
2/9
Piotroski Score
0.6
Altman Z-Score
Insider Signal
BUYING
11 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Scanlan Sean F. | officer | Sale | 207 | - | Oct 24, 2026 |
| Treace John T. | director officer 10% owner | Buy | 22,887 | $93K | Jun 11, 2026 |
| Treace John T. | director officer 10% owner | Buy | 9,891 | $40K | Jun 11, 2026 |
| Treace John T. | director officer 10% owner | Buy | 29,430 | $118K | Jun 10, 2026 |
| Treace John T. | director officer 10% owner | Buy | 14,715 | $59K | Jun 10, 2026 |
| Treace John T. | director officer 10% owner | Buy | 50,000 | $178K | Jun 1, 2026 |
| Treace John T. | director officer 10% owner | Buy | 61,202 | $185K | May 28, 2026 |
| Treace John T. | director officer 10% owner | Buy | 49,810 | $143K | May 27, 2026 |
| Treace John T. | director officer 10% owner | Buy | 4,508 | $13K | May 26, 2026 |
| BAKEWELL JOHN K | director | Buy | 30,000 | - | May 19, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
1.6%
3yr Revenue CAGR
14.5%
EPS Growth YoY
-3.33%
FCF Growth YoY
39.5%
Revenue Trend
STRONG
SEPT Investing tracks real-time dark pool institutional trades for TMCI, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 15:04:44 | $5.00 | 2,522 | $$13K | SELL |
| 15:02:12 | $5.08 | 1,900 | $$10K | BUY |
| 14:30:04 | $5.03 | 1,845 | $$9K | BUY |
| 20:59:06 | $5.04 | 1,096 | $$6K | SELL |
| 20:04:45 | $5.04 | 5,000 | $$25K | BUY |
5 dark pool trades shown · $$62K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for TREACE MEDICAL CONCEPTS, INC. (TMCI) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (6 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →TREACE MEDICAL CONCEPTS, INC. (TMCI) is at $5.01, down 0.89% (-$0.04) at the Nov 12, 2026 close.
Latest TMCI news — Nov 9, 2026: Stifel lifts its rating on Treace Medical Concepts · Nov 9, 2026: Stifel raises Treace Medical Concepts to Buy, price target to $6.5
Treace Medical Concepts reported third-quarter 2026 results, posting a narrower-than-expected loss of $0.19 per share versus the $0.25 analysts forecast, with revenue of $48.253 million beating the $47.800 million estimate. The company also tightened its full-year 2026 sales outlook to $206M-$210M from a prior $204M-$212M range, with the midpoint near the $207.5 million analyst estimate.
The average analyst price target for TMCI is $5.00, ranging from $5 to $5, based on 1 analysts. Latest: Truist Securities maintains on Aug 10, 2026.
Analyst ratings for TMCI: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
TMCI last reported on Nov 6, 2026: EPS -$0.19 vs -$0.25 expected — a beat of 25.2%.
TMCI does not currently pay a dividend.
TREACE MEDICAL CONCEPTS, INC. reported $56M of debt and $13M of cash (Jun 30, 2026).
Support: $4.68, $4.25, $3.83. Resistance: $5.25, $5.78, $6.65.
Insider activity: BUYING, 11 buys and 0 sells in the last 90 days.
Nov 9, 2026: Stifel lifts its rating on Treace Medical Concepts · Nov 9, 2026: Stifel raises Treace Medical Concepts to Buy, price target to $6.5 · Nov 6, 2026: Treace Medical Concepts posts third quarter 2026 financial results